Protara Therapeutics (TARA) Accounts Payables (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Accounts Payables of $4.0 million for Q1 2026, up 74.5% year-over-year from $2.3 million in Q1 2025, and up 16.23% quarter-over-quarter from $3.5 million in Q4 2025.
Protara Therapeutics (TARA) Accounts Payables (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Accounts Payables for 14 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 74.5% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 74.5% YoY), while the FY2025 annual figure was $3.5 million, down 21.7% from the prior year.
- Accounts Payables improved to $4.0 million in Q1 2026 per TARA's latest filing, from $3.5 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.3 million in Q2 2025 and bottomed at $392000.0 in Q2 2022.
- Historically, Accounts Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2025.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 654.34% — and 2024, when it sank 76.18%.
- Protara Therapeutics' Accounts Payables stood at $1.6 million in 2022, then surged by 53.47% to $2.4 million in 2023, then surged by 81.96% to $4.4 million in 2024, then retreated by 21.7% to $3.5 million in 2025, then grew by 16.23% to $4.0 million in 2026.
- Business Quant data shows TARA's Accounts Payables at $4.0 million in Q1 2026, $3.5 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 4.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.66 Mn |
| Mar 31, 2026 | 4.03 Mn |
| Dec 31, 2025 | 3.47 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 2.30 Mn |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 972,000.00 |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 2.50 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 4.08 Mn |
| Dec 31, 2022 | 1.59 Mn |
| Sep 30, 2022 | 456,000.00 |
| Jun 30, 2022 | 392,000.00 |
| Mar 31, 2022 | 541,000.00 |
| Dec 31, 2021 | 954,000.00 |
| Sep 30, 2021 | 928,000.00 |